Galectin Therapeutics (GALT) ( (GALT) ) has released its Q1 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease and cancer, leveraging its expertise in galectin science. In its latest earnings report for the quarter ending March 31, 2025, the company disclosed a significant decrease in cash and cash equivalents, down to $7.4 million from $15.1 million at the end of 2024, highlighting ongoing financial challenges. The company reported a net loss of $9.6 million for the quarter, an improvement from the $11.5 million loss in the same period last year, driven by reduced operating expenses. Despite the losses, Galectin Therapeutics continues to invest in research and development, with expenses amounting to $6.5 million for the quarter. The company is actively managing its financial resources, including a line of credit from its chairman, to support operations through August 2025. Looking ahead, Galectin Therapeutics aims to secure additional funding through various strategic avenues to sustain its operations and advance its clinical programs.